Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products > 

Ibandronic acid

Catalog

Related Products

Others Products

Basic Information post buying leads Suppliers
Name Ibandronic acid EINECS
CAS No. 114084-78-5 Density 1.449 g/cm3
Solubility Melting Point 113-115 ºC
Formula C9H23NO7P2 Boiling Point 587.8 ºC at 760 mm
Molecular Weight 317.23 Flash Point 309.3 ºC
Transport Information Appearance white solid
Safety Risk Codes
Molecular Structure Molecular Structure of 114084-78-5 (Ibandronic acid) Hazard Symbols
Synonyms

Phosphonicacid, [1-hydroxy-3-(methylpentylamino)propylidene]bis- (9CI);BPH 24;Ibandronate;[1-Hydroxy-3-(methylpentylamino)propylidene]diphosphonic acid;

 

Chemistry

IUPAC Name: [ 1-hydroxy-3-[ methyl ( pentyl ) amino ]-1-phosphonopropyl ] phosphonic acid
Synonyms of Ibandronic acid (CAS NO.114084-78-5): Ibandronic acid-D3 ;{ 1-Hydroxy-3-( methylpentylamino ) propylidene ]bisphosphnic Acid ; [1-Hydroxy-3-( methyl-d3-pentylamino ) propylidene ] bisphosphnic Acid ; Ibandronic ;1-Hydroxy-3-( methylpentylamino ) propylidene bisphosphonic acid ; Ibandronic acid ; P,P'-[ 1-Hydroxy-3-( methylpentylamino ) propylidene ] bisphosphonic Acid
Following is the molecular structure: 

CAS NO: 114084-78-5
Classification Code: Bone Density Conservation Agents
Molecular Formula: C9H23NO7P2
Molecular Weight: 319.2289
Melting Point: 113-115°C 
Polar Surface Area: 103.15 Å2
Index of Refraction: 1.537
Molar Refractivity: 68.85 cm3
Molar Volume: 220.2 cm3
Surface Tension: 70.8 dyne/cm
Density: 1.449 g/cm3
Flash Point: 309.3 °C
Enthalpy of Vaporization: 100.74 kJ/mol
Boiling Point: 587.8 °C at 760 mmHg
Vapour Pressure: 2.88E-16 mmHg at 25°C 

Uses

The uses of Ibandronic acid (CAS NO.114084-78-5): 
1.Ibandronic acid (INN) or ibandronate sodium (USAN), marketed under the trade names Boniva, Bondronat and Bonviva, is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis.
2.It may also be used to treat hypercalcemia (elevated blood calcium levels). It is Marketed and Manufactured by GlaxoSmithKline and Roche Laboratories.

Specification

Indications of Ibandronic acid (CAS NO.114084-78-5): Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. Men should not take ibandronate unless they are participating in clinical trials. In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily, 2.50 mg dose treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial of 2,946 women suffering post-menopausal osteoporosis. The participants received either a placebo or an oral ibandronate dose (2.50 mg), or intermittently (20 mg every second day in 12 doses at the beginning of each 3-month interval). Every participant also received daily oral doses of 500 mg of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 per cent when compared to the effects of the placebo drug.

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields